Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 9 |
NetGPI | no | yes: 0, no: 9 |
Term | Name | Level | Count |
---|---|---|---|
GO:0016020 | membrane | 2 | 7 |
GO:0110165 | cellular anatomical entity | 1 | 7 |
Related structures:
AlphaFold database: A4HKP0
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 131 | 135 | PF00656 | 0.642 |
CLV_NRD_NRD_1 | 147 | 149 | PF00675 | 0.403 |
CLV_NRD_NRD_1 | 63 | 65 | PF00675 | 0.584 |
CLV_PCSK_KEX2_1 | 147 | 149 | PF00082 | 0.411 |
CLV_PCSK_KEX2_1 | 63 | 65 | PF00082 | 0.584 |
CLV_PCSK_SKI1_1 | 11 | 15 | PF00082 | 0.607 |
CLV_PCSK_SKI1_1 | 50 | 54 | PF00082 | 0.553 |
DEG_SCF_FBW7_1 | 1 | 8 | PF00400 | 0.368 |
DOC_MAPK_MEF2A_6 | 39 | 48 | PF00069 | 0.391 |
DOC_PP1_RVXF_1 | 103 | 109 | PF00149 | 0.361 |
DOC_USP7_MATH_1 | 5 | 9 | PF00917 | 0.366 |
DOC_WW_Pin1_4 | 1 | 6 | PF00397 | 0.376 |
LIG_14-3-3_CanoR_1 | 128 | 133 | PF00244 | 0.509 |
LIG_14-3-3_CanoR_1 | 139 | 145 | PF00244 | 0.584 |
LIG_14-3-3_CanoR_1 | 50 | 55 | PF00244 | 0.293 |
LIG_Actin_WH2_2 | 77 | 92 | PF00022 | 0.388 |
LIG_APCC_ABBAyCdc20_2 | 147 | 153 | PF00400 | 0.593 |
LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.454 |
LIG_BRCT_BRCA1_1 | 5 | 9 | PF00533 | 0.421 |
LIG_deltaCOP1_diTrp_1 | 107 | 113 | PF00928 | 0.265 |
LIG_FHA_1 | 12 | 18 | PF00498 | 0.405 |
LIG_FHA_1 | 29 | 35 | PF00498 | 0.417 |
LIG_FHA_1 | 84 | 90 | PF00498 | 0.378 |
LIG_LIR_Gen_1 | 40 | 51 | PF02991 | 0.378 |
LIG_LIR_Nem_3 | 107 | 111 | PF02991 | 0.272 |
LIG_LIR_Nem_3 | 40 | 46 | PF02991 | 0.393 |
LIG_LIR_Nem_3 | 79 | 84 | PF02991 | 0.397 |
LIG_NRBOX | 128 | 134 | PF00104 | 0.556 |
LIG_NRP_CendR_1 | 160 | 162 | PF00754 | 0.453 |
LIG_PTB_Apo_2 | 149 | 156 | PF02174 | 0.548 |
LIG_PTB_Phospho_1 | 149 | 155 | PF10480 | 0.544 |
LIG_SH2_SRC | 43 | 46 | PF00017 | 0.325 |
LIG_SH2_STAP1 | 115 | 119 | PF00017 | 0.308 |
LIG_SH2_STAT3 | 65 | 68 | PF00017 | 0.385 |
LIG_SH2_STAT5 | 121 | 124 | PF00017 | 0.291 |
LIG_SH2_STAT5 | 155 | 158 | PF00017 | 0.708 |
LIG_SH2_STAT5 | 43 | 46 | PF00017 | 0.382 |
LIG_SH2_STAT5 | 65 | 68 | PF00017 | 0.446 |
LIG_TRAF2_2 | 102 | 107 | PF00917 | 0.366 |
MOD_CMANNOS | 110 | 113 | PF00535 | 0.308 |
MOD_GSK3_1 | 1 | 8 | PF00069 | 0.435 |
MOD_GSK3_1 | 50 | 57 | PF00069 | 0.385 |
MOD_GSK3_1 | 9 | 16 | PF00069 | 0.368 |
MOD_NEK2_1 | 22 | 27 | PF00069 | 0.319 |
MOD_NEK2_1 | 89 | 94 | PF00069 | 0.373 |
MOD_NEK2_1 | 9 | 14 | PF00069 | 0.406 |
MOD_PKA_2 | 66 | 72 | PF00069 | 0.472 |
MOD_PKA_2 | 89 | 95 | PF00069 | 0.374 |
MOD_Plk_4 | 128 | 134 | PF00069 | 0.556 |
MOD_Plk_4 | 5 | 11 | PF00069 | 0.487 |
MOD_Plk_4 | 89 | 95 | PF00069 | 0.374 |
MOD_ProDKin_1 | 1 | 7 | PF00069 | 0.373 |
MOD_SUMO_rev_2 | 79 | 84 | PF00179 | 0.480 |
TRG_ENDOCYTIC_2 | 115 | 118 | PF00928 | 0.284 |
TRG_ENDOCYTIC_2 | 43 | 46 | PF00928 | 0.370 |
TRG_ENDOCYTIC_2 | 59 | 62 | PF00928 | 0.362 |
TRG_ER_diArg_1 | 159 | 162 | PF00400 | 0.646 |
TRG_ER_diArg_1 | 62 | 64 | PF00400 | 0.383 |
TRG_Pf-PMV_PEXEL_1 | 15 | 20 | PF00026 | 0.631 |
TRG_Pf-PMV_PEXEL_1 | 64 | 68 | PF00026 | 0.586 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N0P5P2 | Leptomonas seymouri | 85% | 100% |
A0A1X0NS66 | Trypanosomatidae | 66% | 100% |
A0A3Q8ILB8 | Leishmania donovani | 89% | 100% |
A0A3R7L0F6 | Trypanosoma rangeli | 66% | 99% |
A4I871 | Leishmania infantum | 90% | 100% |
D0AAE0 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 62% | 100% |
E9B329 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 91% | 100% |
Q4Q525 | Leishmania major | 90% | 100% |